Stay updated on Clinical Trial: Camlipixant PK with Rifampin and Rabeprazole
Sign up to get notified when there's something new on the Clinical Trial: Camlipixant PK with Rifampin and Rabeprazole page.

Latest updates to the Clinical Trial: Camlipixant PK with Rifampin and Rabeprazole page
- Check4 days agoNo Change Detected
- Check12 days agoChange DetectedA new page revision v3.6.5 was added, and the previous revision v3.6.4 was removed, reflecting an updated version of the study record.SummaryDifference0.1%

- Check19 days agoNo Change Detected
- Check26 days agoChange DetectedRevision tag updated from v3.6.3 to v3.6.4 on the page, indicating a small update to the study record presentation. The underlying study details and criteria remain unchanged.SummaryDifference0.1%

- Check48 days agoChange DetectedRevision bump from v3.6.2 to v3.6.3 indicates a new release of the ClinicalTrials.gov interface. This change appears to be a minor platform update and does not modify study content or details.SummaryDifference0.1%

- Check55 days agoChange DetectedRevision updated from v3.6.0 to v3.6.2, indicating a newer version of the page documentation. This update reflects metadata and does not change the study details or participant information.SummaryDifference0.1%

- Check69 days agoChange DetectedRecruitment status is shown as closed, and new help sections (How to Read a Study Record, Common Questions, How to Join a Study) along with a revised Intervention/Treatment heading were added; the revision tag was updated to v3.6.0.SummaryDifference0.4%

- Check77 days agoChange DetectedThe revision line changed from v3.5.4 to v3.5.5, representing a new version of the page content. This is a metadata update rather than a substantive change to the study details or results.SummaryDifference0.1%

Stay in the know with updates to Clinical Trial: Camlipixant PK with Rifampin and Rabeprazole
Enter your email address, and we'll notify you when there's something new on the Clinical Trial: Camlipixant PK with Rifampin and Rabeprazole page.